Author: Cozine, Taryn ; Gollapudi, Deepika ; Lei, Q. Paula ; Schneck, Nicole A. ; Ivleva, Vera B. ; Ragheb, Daniel ; Patel, Aakash ; Gowetski, Daniel B. ; Barefoot, Nathan ; Cai, Cindy X.

For conjugated HIV-1 fusion peptide vaccine development, recombinant Tetanus toxoid heavy chain fragment C (rTTHC) was applied as a carrier protein to boost peptide immunogenicity. Understanding the characteristics of rTTHC is the first step prior to the peptide conjugation. A comprehensive mass spectrometry (MS) characterization was performed on E. coli expressed rTTHC during its purification process. Intact mass along with peptide mapping analysis discovered the existence of three cysteine modification forms: glutathionylation, trisulfide bond modification, and disulfide bond shuffling, in correlation to a three-peak profile during a hydrophobic interaction chromatography (HIC) purification step. Coexistence of these multiple oxidative forms indicated that the active thiols underwent redox reaction in the rTTHC material. Identity confirmation of the rTTHC carrier protein by MS analysis provided pivotal guidance to assess the purification step and helped ensure that vaccine development could proceed.

09 Dec 2019·Angewandte Chemie International EditionQ1 · CHEMISTRY

A DNA–Azobenzene Nanopump Fueled by Upconversion Luminescence for Controllable Intracellular Drug Release

Q1 · CHEMISTRY

Article

Author: He, Yuling ; Zhang, Xiaobo ; Zhang, Yue ; Song, Guobin ; Ju, Huangxian ; Liu, Ying

AbstractStimulus‐responsive drug release possesses considerable significance in cancer therapy. This work reports an upconversion‐luminescence‐fueled DNA–azobenzene nanopump for rapid and efficient drug release. The nanopump is constructed by assembling the azobenzene‐functionalized DNA strands on upconversion nanoparticles (UCNPs). Doxorubicin (DOX) is loaded in the nanopump by intercalation in the DNA helix. Under NIR light, the UCNPs emit both UV and visible photons to fuel the continuous photoisomerization of azo, which acts as an impeller pump to trigger cyclic DNA hybridization and dehybridization for controllable DOX release. In a relatively short period, this system demonstrates 86.7 % DOX release. By assembling HIV‐1 TAT peptide and hyaluronic acid on the system, targeting of the cancer‐cell nucleus is achieved for perinuclear aggregation of DOX and enhanced anticancer therapy. This highly effective drug delivery nanopump could contribute to chemotherapy development.

01 Dec 2018·Proteins: Structure, Function, and BioinformaticsQ3 · BIOLOGY

Prediction of cross‐clade HIV‐1 T‐cell epitopes using immunoinformatics analysis

Q3 · BIOLOGY

Article

Author: Bolhassani, Azam ; Kardani, Kimia ; Namvar, Ali ; Khairkhah, Niloofar

AbstractEpitope mapping has emerged as a powerful tool to develop peptide vaccines against hypervariable viruses such as HIV. This method has led to stimulate a specific immune response and achieve advanced vaccine formulations. In this study, we identified peptides that were potentially immunostimulatory and highly conserved in HIV‐1 main group. The analyses included were CTL assay, Tap transport, and the potential allergenicity. The highest population coverage rate was also found for all potential T‐cell epitopes in 16 specified geographic regions of the world. The current study is the first attempt to explore peptide‐protein flexible docking across all the major epitopes of HIV‐1. Our data indicated that REV54‐63and VPU58‐66 with the highest epitope identification scores, GP16037‐46 and VPR38‐47 with the highest conservation (98.89%), and NEF134‐144 and GP16037‐46 epitopes with a higher quality of peptide‐protein interaction models in docking procedure were chosen as putative epitopes among all HLA class I epitopes. TAT40‐67, VPR65‐82, and VPU30‐44 with the highest score of binding affinity, VPR65‐82 with the highest conservation (97.55%), and GP160481‐498 epitope with a higher quality of peptide‐protein interaction models in docking procedure were determined as putative epitopes among all HLA‐DR epitopes. Furthermore, two epitopes of GP160481‐498 and VIF144‐159 were predicted to bind 22 and 21 HLA‐II alleles, respectively. Accumulative population coverage of potential helper T‐cell epitopes and CTL epitopes varied between 90.82% and 100%. Generally, these predicted highly immunogenic T‐cell epitopes can contribute to design HIV‐1 peptide vaccine candidates. Combination of bioinformatics tools with in vivo methods will be necessary for HIV‐1 vaccine development.

100 Deals associated with HIV-1 peptide vaccine(United Biomedical, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	US	United Biomedical, Inc.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

HIV-1 peptide vaccine(United Biomedical, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation